BMS-986523

BMS-986523 is an investigational, targeted oncology agent being developed by Bristol Myers Squibb for the treatment of advanced solid tumors characterized by KRAS mutation or amplification. Early-phase clinical evaluation is ongoing in a Phase 1/2a, open-label, multicenter trial assessing BMS-986523 as monotherapy and in combination with standard anti-cancer agents including gemcitabine, nab-paclitaxel, cetuximab, and pembrolizumab in participants with unresectable or metastatic solid malignancies.[1][5][10][3][11] While the precise molecular target and modality have not been publicly disclosed, trial design and eligibility criteria indicate a mechanism directed at KRAS-driven tumors, with objectives to characterize safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity.[1][3][5][10][11]